# LEGEND-T2DM Evidence Dissemination Summary

Target: **empagliflozin**, Comparator: **glimepiride** Outcome: **Edema**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	3,464	2,891	47	16.26
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	178,442	139,397	2,677	19.20
Merative CCAE	11,741	9,085	308	33.90
Merative MDCD	1,435	782	64	81.84
Merative MDCR	1,327	821	50	60.86
Optum Clinformatics	13,902	10,257	529	51.57
Optum EHR	14,139	6,441	189	29.35
Veterans Affairs	36,754	26,136	785	30.03

How Reliable Are the Effect Estimates? (Objective diagnostics)

What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)